Daewoong to file overseas patent application over new dementia treatment

Daewoong Pharm and Medifron DBT, a pharmaceutical company specializing in the development of neurological treatments, said on March 10 it will jointly file its patent application of DBT-1339, a novel treatment for Alzheimer's dementia, in 20 countries including the U.S. and Japan.

DBT-1339 is a beta amyloid that has the capability of attacking toxins that cause harm to neural cells. There is...